||CYM5442 is an S1P agonist, targeting to Sphingosine.
||Fingolimod, a novel immune modulator, is a sphingosine 1-phosphate (S1P) antagonist (IC50: 0.033 nM in K562 and NK cells).
||Ponesimod is an orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist that acts as a functional antagonist, with potential immunomodulating activity.
||CYM-5541 is a selective and allosteric S1P3 receptor agonist.
||An S1P receptor agonist.
||PF-543, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM.
||BAF312 (Siponimod), a next-generation S1P receptor modulator, is specific for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM,respectively. The specificity of BAF312 for S
||SKI II is a highly selective and non-ATP-competitive S1P receptor inhibitor (IC50: 0.5 μM) while exhibiting no inhibitory action on other kinases including PKCα, PI3K, and ERK2.
||ABC294640 is an orally active and specific sphingosine kinase-2 (SphK2) inhibitor (IC50: 60 μM).
||Ozanimod (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis,
||MHP is an activator of sphingosine kinase (SPHK1), and significantly stimulates CAMP mRNA and protein production in KC.
||GSK2018682 is an agonist of sphingosine-1-phosphate receptor (s1p1) and (s1p5) agonist(pEC50s of 7.7 and 7.2,respectively).
||K145 is a specific inhibitor of SphK2 (IC50: 4.30 μM), while no inhibition of SphK1 at concentrations up to 10 μM.
||Etrasimod (APD334) is a specific and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor (IC50: 1.88 nM in CHO cells).
||Phorbol 12-myristate 13-acetate
||Phorbol 12-myristate 13-acetate (PMA) is a dual SphK and PKC activator.
||Fingolimod is an antagonist of sphingosine 1-phosphate (S1P) (IC50 of 0.033 nM in K562 and NK cells).
||PF-543 Citrate is an inhibitor of sphingosine-competitive SPHK1(IC50 of 2 nM ).
||PF429242 dihydrochloride is a reversible and competitive inhibitor of S1P (IC50 of 175 nM).
||ASP-4058 is a selective and oral bioactive agonist for S1P1 and S1P5. It ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
||SK1-IN-1 is a potent inhibitor of sphingosine kinase 1 (SPHK1)(IC50 of 58 nM).
||KD-3010 is a orally, potent active, and selective PPARδ agonist.
||TY-52156 is an effective and selective S1P3 receptor antagonist (Ki: 110 nM).
||VPC 23019 is a competitive antagonist at the S1P1 and S1P3 receptors (pKi= 7.86 and 5.93, respectively). It is also an agonist at the S1P4 and S1P5 receptors (pEC50= 6.58 and 7.07,